Comment on CMS-2026-1255-0001
Prime Therapeutics LLCSupportBusiness
Summary: Prime Therapeutics LLC, a pharmacy solutions partner, supports the proposed rule to modernize prior authorization and improve interoperability. However, they request several refinements, including extended compliance deadlines for medical-benefit drug prior authorization and Medicaid RTPB implementation, as well as clarifications on when the decision clock begins to avoid administrative cycles.
Please find attached Prime Therapeutics LLC's comments on CMS-OO62-P, 2026 Interoperability Standards and Prior Authorization for Drugs Proposed Rule.
Thank you for the opportunity to provide feedback on the proposed rule.
Sincerely,
Prime Therapeutics LLC